An AI-guided mRNA therapeutics platform that selectively programs target cells in vivo for cancer and autoimmune disease treatment.
Kernal Biologics is developing an mRNA 2.0 therapeutics platform that delivers mRNA-LNP constructs to specific target cells in vivo, enabling scalable in vivo CAR-T programming without costly ex vivo manufacturing. The platform uses AI-guided design to ensure selective translation in specific tissues, achieving over 90% delivery efficiency with T-cell-targeted LNPs. The lead program KR-402 targets B-cell depletion for cancer and autoimmune diseases. Kernal mRNA Platform is a product of Kernal Biologics.